Anavex Life Sciences Corp (AVXL)

[falconer66a]

There will be no useful competition.

...273's overall market share could diminish as competitors come on line,....

Will there be “competitors” for Anavex 2-73 (blarcamesine)?

They already exist. There are 29: https://www.drugs.com/condition/alzheimer-s-disease.html

Blarcamesine’s market share wil not be determined by, nor controlled by the number of different competing drugs. Market share will be determined solely by our drug’s ability to prevent or treat Alzheimer’s. Inasmuch as no other drug has blarcamesine’s unique, propitious mechanism of action (MOA), which works “upstream,” at the root cause(s) of Alzheimer’s, by activation of the sigma-1 receptor protein, each and every competing drug will fail to safely and persistently attain favorable therapeutic outcomes. With the competing drugs, symptoms will be incompletely suppressed, the disease will continue to progress at rates greater than with blarcamesine (which will either stop progression, or actually reverse it).

Anyone seen any data on new or prospective drugs that, like blarcamesine, work at the root, exact cause of Alzheimer’s, at the sigma-1 receptor protein, that, like blarcamesine, restore healthful homeostatic processes in the neuron? Nope. They don’t exist. All of the competitors are still working to fix downstream things (such as beta-amyloid or tau pathologies, after they form).

Blarcamesine does not, and once approved, will not have any effective competition. Anavex Life Sciences Corp will own the Alzheimer’s treatment (and prevention) market. Keeping Grandma, with Alzheimer’s, alive for a few more months won’t cut it. She, and her doctor, will demand treatment with blarcamesine.